Investigational drug · Phase 3
Buagafuran
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Generalized Anxiety Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Buagafuran"
First trial start
2023
Jul 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Buagafuran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Anxiety Disorder
Approved drugs for the same conditions: Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Buagafuran" as an intervention, largest first.
- Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GADPivotal-lookingRecruiting
Beijing Union Pharmaceutical Factory LtdIndustry
NCT06243640 · 504 participants (planned) · Start Jul 25, 2023 · Primary completion Jun 30, 2026
Drug: Buagafuran capsules, 15mg/ capsule; Buagafuran capsules mimic, 0mg/ capsule · For: Generalized Anxiety Disorder
Sites: Beijing, China
- Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GADPivotal-lookingRecruiting
Beijing Union Pharmaceutical Factory LtdIndustry
NCT06243614 · 410 participants (planned) · Start Jul 24, 2023 · Primary completion Jun 30, 2026
Drug: Buagafuran capsules, 15mg/ capsule; Buspirone tablets, 5mg/ tablet and 2 more · For: Generalized Anxiety Disorder
Sites: Beijing, China
- Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic FunctionNot yet recruiting
Beijing Union Pharmaceutical Factory LtdIndustry
NCT07457190 · 24 participants (planned) · Start Mar 2026 · Primary completion Aug 2026
Drug: Buagafuran · For: Generalized Anxiety Disorder
Sites: Beijing, China
- Study on the Drug Interaction Between Buagafuran and VoriconazoleNot yet recruiting
Beijing Union Pharmaceutical Factory LtdIndustry
NCT07457203 · 18 participants (planned) · Start Apr 2026 · Primary completion May 2026
Drug: Buagafuran; Voriconazole · For: Drug Drug Interaction (DDI)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human.
Yang F, Wang B, Liu Z, et al. · Front Pharmacol 2017
- [Analysis and identification of degradation products of buagafuran by high performance liquid chromatography-diode array detection-tandem mass spectrometry].
Xia XJ, He JM, Li C, et al. · Yao Xue Xue Bao 2013
- Simultaneous determination of a novel anxiolytic agent buagafuran and one metabolite in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
Yang F, Wang H, Zhao Q, et al. · J Pharm Biomed Anal 2013
- Quantitative determination of buagafuran in human plasma by liquid chromatography-tandem mass spectrometry.
Yang F, Wang H, Peng A, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2011
- Pharmacokinetics, tissue distribution, and excretion of buagafuran in rats.
Hu JP, Wang WJ, Chen H, et al. · J Asian Nat Prod Res 2011
- Effect of buagafuran on liver microsomal cytochrome P450 in rats.
Li E, Hu JP, Wang BL, et al. · J Asian Nat Prod Res 2010
Also in development for Generalized Anxiety Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- Buagafuran mimicPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Toludesvenlafaxine Hydrochloride Sustained-releasePhase 31 trial
Luye Pharma Group Ltd. · Generalized Anxiety Disorder
- ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials
Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder
- RE104Phase 23 trials
Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression
- CYB004Phase 21 trial
Cybin IRL Limited · Generalized Anxiety Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.